Molecular structure of thyroxine, the deficiency of which causes the symptoms of hypothyroidism
|Classification and external resources|
Hypothyroidism (//; from hypo- meaning under or reduced, plus thyroid), often called underactive thyroid or low thyroid and sometimes hypothyreosis, is a common endocrine disorder in which the thyroid gland does not produce enough thyroid hormone. It can cause a number of symptoms, such as tiredness, poor ability to tolerate cold, and weight gain. In children, hypothyroidism leads to delays in growth and intellectual development, which is called cretinism in severe cases. The diagnosis of hypothyroidism, when suspected, can be confirmed with blood tests measuring thyroid-stimulating hormone (TSH) and thyroxine levels.
Worldwide, too little iodine in the diet is the most common cause of hypothyroidism. In countries with enough dietary iodine, the most common cause of hypothyroidism is the autoimmune condition Hashimoto's thyroiditis. Less common causes include the following: previous treatment with radioactive iodine, injury to the hypothalamus or the anterior pituitary gland, certain medications, a lack of a functioning thyroid at birth, or previous thyroid surgery.
Hypothyroidism can be treated with manufactured levothyroxine; the dose is adjusted according to symptoms and normalization of the thyroxine and TSH levels. In Western countries, hypothyroidism occurs in 0.3–0.4% while subclinical hypothyroidism, a milder form of hypothyroidism characterized by normal thyroxine levels and an elevated TSH level, is thought to occur in 4.3–8.5%. Dogs are also known to develop hypothyroidism and in rare circumstances cats and horses can also have the disorder.
- 1 Signs and symptoms
- 2 Causes
- 3 Pathophysiology
- 4 Diagnosis
- 5 Prevention
- 6 Screening
- 7 Management
- 8 Epidemiology
- 9 History
- 10 Other animals
- 11 References
- 12 Further reading
- 13 External links
Signs and symptoms
People with hypothyroidism often have no or only mild symptoms. Numerous symptoms and signs are associated with hypothyroidism, and can be related to the underlying cause, or a direct effect of having not enough thyroid hormones. Hashimoto's thyroiditis may present with the mass effect of a goiter (enlarged thyroid gland).
|Fatigue||Dry, coarse skin|
|Feeling cold||Cool extremities|
|Poor memory and concentration||Myxedema (mucopolysaccharide deposits in the skin)|
|Constipation, dyspepsia||Hair loss|
|Weight gain with poor appetite||Slow pulse rate|
|Shortness of breath||Swelling of the limbs|
|Hoarse voice||Delayed relaxation of tendon reflexes|
|In females, heavy menstrual periods (and later light periods)||Carpal tunnel syndrome|
|Abnormal sensation||Pleural effusion, ascites, pericardial effusion|
Myxedema coma is a rare but life-threatening state of extreme hypothyroidism. It may occur in those who are known to have hypothyroidism when they develop another illness, but it can be the first presentation of hypothyroidism. The illness is characterized by very low body temperature without shivering, confusion, a slow heart rate and reduced breathing effort. There may be physical signs suggestive of hypothyroidism, such as skin changes or enlargement of the tongue.
Even mild or subclinical hypothyroidism has been associated with impaired fertility and an increased risk of miscarriage. Hypothyroidism in early pregnancy, even with limited or no symptoms, may increase the risk of pre-eclampsia, offspring with lower intelligence, and the risk of infant death around the time of birth. Women are affected by hypothyroidism in 0.3–0.5% of pregnancies. Subclinical hypothyroidism during pregnancy has also been associated with gestational diabetes and birth of the baby before 37 weeks of pregnancy.
Newborn children with hypothyroidism may have normal birth weight and height (although the head may be larger than expected and the posterior fontanelle may be open). Some may have drowsiness, decreased muscle tone, a hoarse-sounding cry, feeding difficulties, constipation, an enlarged tongue, umbilical hernia, dry skin, a decreased body temperature and jaundice. A goiter is rare, although it may develop later in children who have a thyroid gland that does not produce functioning thyroid hormone. A goiter may also develop in children growing up in areas with iodine deficiency. Normal growth and development may be delayed, and not treating infants may lead to an intellectual impairment (IQ 6–15 points lower in severe cases). Other problems include the following: large scale and fine motor skills and coordination, reduced muscle tone, squinting, decreased attention span, and delayed speaking. Tooth eruption may be delayed.
In older children and adolescents, the symptoms of hypothyroidism may include fatigue, cold intolerance, sleepiness, muscle weakness, constipation, a delay in growth, overweight for height, pallor, coarse and thick skin, increased body hair, irregular menstrual cycles in girls, and delayed puberty. Signs may include delayed relaxation of the ankle reflex and a slow heart beat. A goiter may be present with a completely enlarged thyroid gland; sometimes only part of the thyroid is enlarged and it can be knobby in character.
Hypothyroidism is caused by inadequate function of the gland itself (primary hypothyroidism) or by not enough stimulation by thyroid-stimulating hormone (central hypothyroidism). Primary hypothyroidism is about a thousandfold more common than central hypothyroidism.
Iodine deficiency is the most common cause of primary hypothyroidism and endemic goiter worldwide. In areas of the world with sufficient dietary iodine, hypothyroidism is most commonly caused by the autoimmune disease Hashimoto's thyroiditis (chronic autoimmune thyroiditis). Hashimoto's may be associated with a goiter. It is characterized by infiltration of the thyroid gland with T lymphocytes and autoantibodies against specific thyroid antigens such as thyroid peroxidase, thyroglobulin and the TSH receptor.
After women give birth, about 5% develop postpartum thyroiditis which can occur up to nine months afterwards. This is characterized by a short period of hyperthyroidism followed by a period of hypothyroidism; 20–40% remain permanently hypothyroid.
Autoimmune thyroiditis is associated with other immune-mediated diseases such as diabetes mellitus type 1, pernicious anemia, myasthenia gravis, celiac disease, rheumatoid arthritis and systemic lupus erythematosus. It may occur as part of autoimmune polyendocrine syndrome (type 1 and type 2).
|Primary hypothyroidism||Iodine deficiency (developing countries), autoimmune thyroiditis, previous thyroidectomy, previous radioiodine treatment, previous external beam radiotherapy to the neck
Medication: lithium-based mood stabilizers, amiodarone, interferon alpha, tyrosine kinase inhibitors such as sunitinib
|Central hypothyroidism||Lesions compressing the pituitary (pituitary adenoma, craniopharyngioma, meningioma, glioma, Rathke's cleft cyst, metastasis, empty sella, aneurysm of the internal carotid artery), surgery or radiation to the pituitary, drugs, injury, vascular disorders (pituitary apoplexy, Sheehan syndrome, subarachnoid hemorrhage), autoimmune diseases (lymphocytic hypophysitis, polyglandular disorders), infiltrative diseases (iron overload due to hemochromatosis or thalassemia, sarcoidosis, Langerhans cell histiocytosis), particular inherited congenital disorders, and infections (tuberculosis, mycoses, syphilis)|
|Congenital hypothyroidism||Thyroid dysgenesis (75%), thyroid dyshormonogenesis (20%), maternal antibody or radioiodine transfer
Syndromes: mutations (in GNAS complex locus, PAX8, TTF-1/NKX2-1, TTF-2/FOXE1), Pendred's syndrome (associated with sensorineural hearing loss)
Transiently: due to maternal iodine deficiency or excess, anti-TSH receptor antibodies, certain congenital disorders, neonatal illness
Central: pituitary dysfunction (idiopathic, septo-optic dysplasia, deficiency of PIT1, isolated TSH deficiency)
Thyroid hormone is required for the normal functioning of numerous tissues in the body. In health, the thyroid gland predominantly secretes thyroxine (T4), which is converted into triiodothyronine (T3) in other organs by the selenium-dependent enzyme iodothyronine deiodinase. Triiodothyronine binds to the thyroid hormone receptor in the nucleus of cells, where it stimulates the turning on of particular genes and the production of specific proteins. Additionally, the hormone binds to integrin αvβ3 on the cell membrane, thereby stimulating the sodium–hydrogen antiporter and processes such as formation of blood vessels and cell growth. In blood, almost all thyroid hormone (99.97%) is bound to plasma proteins such as thyroxine-binding globulin; only the free unbound thyroid hormone is biologically active.
The thyroid gland is the only source of thyroid hormone in the body; the process requires iodine and the amino acid tyrosine. Iodine in the bloodstream is taken up by the gland and incorporated into thyroglobulin molecules. The process is controlled by the thyroid-stimulating hormone (TSH, thyrotropin), which is secreted by the pituitary. Not enough iodine, or not enough TSH, can result in decreased production of thyroid hormones.
The hypothalamic–pituitary–thyroid axis plays a key role in maintaining thyroid hormone levels within normal limits. Production of TSH by the anterior pituitary gland is stimulated in turn by thyrotropin-releasing hormone (TRH), released from the hypothalamus. Production of TSH and TRH is decreased by thyroxine by a negative feedback process. Not enough TRH, which is uncommon, can lead to not enough TSH and thereby to not enough thyroid hormone production.
Pregnancy leads to marked changes in thyroid hormone physiology. The gland is increased in size by 10%, thyroxine production is increased by 50%, and iodine requirements are increased. Many women have normal thyroid function but have immunological evidence of thyroid autoimmunity (as evidenced by autoantibodies) or are iodine deficient, and develop evidence of hypothyroidism before or after giving birth.
Laboratory testing of thyroid stimulating hormone levels in the blood is considered the best initial test for hypothyroidism; a second TSH level is often obtained several weeks later for confirmation. Levels may be abnormal in the context of other illnesses, and TSH testing in hospitalized people is discouraged unless thyroid dysfunction is strongly suspected. An elevated TSH level indicates that the thyroid gland is not producing enough thyroid hormone, and free T4 levels are then often obtained. Measuring T3 is discouraged in the assessment for hypothyroidism. There are a number of symptom rating scales for hypothyroidism; they provide a degree of objectivity but have limited use for diagnosis.
|Normal||Normal||Normal thyroid function|
Many cases of hypothyroidism are associated with mild elevations in creatine kinase and liver enzymes in the blood. They typically return to normal when hypothyroidism has been fully treated. Levels of cholesterol, low-density lipoprotein and lipoprotein (a) can be elevated; the impact of subclinical hypothyroidism on lipid parameters is less well-defined.
Very severe hypothyroidism and myxedema coma is characteristically associated with low sodium levels in the blood together with elevations in antidiuretic hormone, as well as acute worsening of kidney function due to a number of causes.
A diagnosis of hypothyroidism without any lumps or masses felt within the thyroid gland does not require thyroid imaging; however, if the thyroid feels abnormal, diagnostic imaging is then recommended. The presence of antibodies against thyroid peroxidase (TPO) makes it more likely that thyroid nodules are caused by autoimmune thyroiditis, but if there is any doubt, a needle biopsy may be required.
If the TSH level is normal or low and serum free T4 levels are low, this is suggestive of central hypothyroidism (not enough TSH or TRH secretion by the pituitary gland or hypothalamus). There may be other features of hypopituitarism, such as menstrual cycle abnormalities and adrenal insufficiency. There might also be evidence of a pituitary mass such as headaches and vision changes. Central hypothyroidism should be investigated further to determine the underlying cause.
In overt primary hypothyroidism, TSH levels are high and T4 and T3 levels are low. Overt hypothyroidism may also be diagnosed in those who have a TSH on multiple occasions of greater than 5mIU/L, appropriate symptoms, and only a borderline low T4. It may also be diagnosed in those with a TSH of greater than 10mIU/L.
Subclinical hypothyroidism is a milder form of hypothyroidism characterized by an elevated serum TSH level, but with a normal serum free thyroxine level. In adults it is diagnosed when TSH levels are greater than 5 mIU/L and less than 10mIU/L. The presentation of subclinical hypothyroidism is variable and classic signs and symptoms of hypothyroidism may not be observed. Of people with subclinical hypothyroidism, a proportion will develop overt hypothyroidism each year. In those with detectable antibodies against thyroid peroxidase (TPO), this occurs in 4.3%, while in those with no detectable antibodies, this occurs in 2.6%. Those with subclinical hypothyroidism and detectable anti-TPO antibodies who do not require treatment should have repeat thyroid function tests more frequently (e.g. yearly) compared with those who do not have antibodies.
During pregnancy, the thyroid gland must produce 50% more thyroid hormone to provide enough thyroid hormone for the developing fetus and the expectant mother. In pregnancy, free thyroxine levels may be lower than anticipated due to increased binding to thyroid binding globulin and decreased binding to albumin. They should either be corrected for the stage of pregnancy, or total thyroxine levels should be used instead for diagnosis. TSH values may also be lower than normal (particularly in the first trimester) and the normal range should be adjusted for the stage of pregnancy.
In pregnancy, subclinical hypothyroidism is defined as a TSH between 2.5 and 10 mIU/l with a normal thyroxine level, while those with TSH above 10 mIU/l are considered to be overtly hypothyroid even if the thyroxine level is normal. Antibodies against TPO may be important in making decisions about treatment, and should therefore be determined in women with abnormal thyroid function tests.
Determination of TPO antibodies may be considered as part of the assessment of recurrent miscarriage, as subtle thyroid dysfunction can be associated with pregnancy loss, but this recommendation is not universal, and presence of thyroid antibodies may not predict future outcome.
Hypothyroidism may be prevented in a population by adding iodine to commonly used foods. This public health measure has eliminated endemic childhood hypothyroidism in countries where it was once common. In addition to promoting the consumption of iodine-rich foods such as dairy and fish, many countries with moderate iodine deficiency have implemented universal salt iodization (USI). Encouraged by the World Health Organization, 130 countries now have USI, and 70% of the world's population are receiving iodized salt. In some countries, iodized salt is added to bread. Despite this, iodine deficiency has reappeared in some Western countries as a result of attempts to reduce salt intake.
Pregnant and breastfeeding women, who require 66% more daily iodine requirement than non-pregnant women, may still not be getting enough iodine. The World Health Organization recommends a daily intake of 250 µg for pregnant and breastfeeding women. As many women will not achieve this from dietary sources alone, the American Thyroid Association recommends a 150 µg daily supplement by mouth.
Screening for hypothyroidism is performed in the newborn period in many countries, generally using TSH. This has led to the early identification of many cases and thus the prevention of developmental delay. It is the most widely used newborn screening test worldwide. While TSH-based screening will identify the most common causes, the addition of T4 testing is required to pick up the rarer central causes of neonatal hypothyroidism. If T4 determination is included in the screening done at birth, this will identify cases of congenital hypothyroidism of central origin in 1:16,000 to 1:160,000 children. Considering that these children usually have other pituitary hormone deficiencies, early identification of these cases may prevent complications.
In adults, widespread screening of the general population is a matter of debate. Some organizations (such as the United States Preventive Services Task Force) state that evidence is insufficient to support routine screening, while others (such as the American Thyroid Association) recommend either intermittent testing above a certain age in both sexes or only in women. Targeted screening may be appropriate in a number of situations where hypothyroidism is common: other autoimmune diseases, a strong family history of thyroid disease, those who have received radioiodine or other radiation therapy to the neck, those who have previously undergone thyroid surgery, those with an abnormal thyroid examination, those with psychiatric disorders, people taking amiodarone or lithium, and those with a number of health conditions (such as certain heart and skin conditions). Yearly thyroid function tests are recommended in people with Down syndrome, as they are at higher risk of thyroid disease.
Most people with hypothyroidism symptoms and confirmed thyroxine deficiency are treated with a synthetic long-acting form of thyroxine, known as levothyroxine (L-thyroxine). In young and otherwise healthy people with overt hypothyroidism, a full replacement dose (adjusted by weight) can be started immediately; in the elderly and people with heart disease a lower starting dose is recommended to prevent over supplementation and risk of complications. Lower doses may be sufficient in those with subclinical hypothyroidism, while people with central hypothyroidism may require a higher than average dose.
Blood free thyroxine and TSH levels are monitored to help determine whether the dose is adequate. This is done 4–8 weeks after the start of treatment or a change in levothyroxine dose. Once the adequate replacement dose has been established, the tests can be repeated after 6 and then 12 months, unless there is a change in symptoms. In people with central/secondary hypothyroidism, TSH is not a reliable marker of hormone replacement and decisions are based mainly on the free T4 level. Levothyroxine is best taken 30–60 minutes before breakfast, or four hours after food, as certain substances such as food and calcium can inhibit the absorption of levothyroxine. There is no direct way of increasing thyroid hormone secretion by the thyroid gland.
Adding liothyronine (synthetic T3) to levothyroxine has been suggested as a measure to provide better symptom control, but this has not been confirmed by studies. In 2007, the British Thyroid Association stated that combined T4 and T3 therapy carried a higher rate of side effects and no benefit over T4 alone. Similarly, American guidelines discourage combination therapy due to a lack of evidence, although they acknowledge that some people feel better when receiving combination treatment. Treatment with liothyronine alone has not received enough study to make a recommendation as to its use; due to its shorter half-life it needs to be taken more often.
People with hypothyroidism who do not feel well despite optimal levothyroxine dosing may request adjunctive treatment with liothyronine. A 2012 guideline from the European Thyroid Association recommends that support should be offered with regards to the chronic nature of the disease, and that other causes for the symptoms should be excluded. Addition of liothyronine should be regarded as experimental, initially only for a trial period of 3 months, and in a set ratio to the current dose of levothyroxine. The guideline explicitly aims to enhance the safety of this approach and to counter its indiscriminate use.
Desiccated animal thyroid
Desiccated thyroid extract is an animal-based thyroid gland extract, most commonly from pigs. It is a combination therapy, containing forms of T4 and T3. It also contains calcitonin (a hormone produced in the thyroid gland involved in the regulation of calcium levels), T1 and T2; these are not present in synthetic hormone medication. This extract was once a mainstream hypothyroidism treatment, but its use today is unsupported by evidence; British Thyroid Association and American professional guidelines discourage its use.
There is little evidence whether there is a benefit from treating subclinical hypothyroidism, and whether this offsets the risks of overtreatment. Untreated subclinical hypothyroidism may be associated with a modest increase in the risk of coronary artery disease. A 2007 review found no benefit of thyroid hormone replacement except for "some parameters of lipid profiles and left ventricular function".
Since 2008, consensus American and British opinion has been that in general people with TSH under 10 mIU/l do not require treatment. American guidelines recommend that treatment be considered if the TSH is elevated but below 10 mIU/l in people with symptoms of hypothyroidism, detectable antibodies against thyroid peroxidase, a history of heart disease or are at an increased risk for heart disease.
Myxedema coma or severe decompensated hypothyroidism usually requires admission to the intensive care, close observation and treatment of abnormalities in breathing, temperature control, blood pressure, and sodium levels. Mechanical ventilation may be required, as well as fluid replacement, vasopressor agents, careful rewarming, and corticosteroids (for possible adrenal insufficiency which can occur together with hypothyroidism). Careful correction of low sodium levels may be achieved with hypertonic saline solutions or vasopressin receptor antagonists. For rapid treatment of the hypothyroidism, levothyroxine or liothyronine may be administered intravenously, particularly if the level of consciousness is too low to be able to safely swallow medication.
In women with known hypothyroidism who become pregnant, it is recommended that serum TSH levels are closely monitored. Levothyroxine should be used to keep TSH levels within the normal range for that trimester. The first trimester normal range is below 2.5 mIU/L and the second and third trimesters normal range is below 3.0 mIU/L. Treatment should be guided by total (rather than free) thyroxine or by the free T4 index. The results should be interpreted according to the appropriate reference range for that stage of pregnancy. The levothyroxine dose usually needs to be increased after pregnancy is confirmed.
Women with anti-TPO antibodies who are trying to become pregnant (naturally or by assisted means) may require thyroid hormone supplementation even if the TSH level is normal. This is particularly true if they have had previous miscarriages or have been hypothyroid in the past. Supplementary levothyroxine may reduce the risk of preterm birth and possibly miscarriage. The recommendation is stronger in pregnant women with subclinical hypothyroidism (defined as TSH 2.5–10 mIU/l) who are anti-TPO positive, in view of the risk of overt hypothyroidism. If a decision is made not to treat, close monitoring of the thyroid function (every 4 weeks in the first 20 weeks of pregnancy) is recommended. If anti-TPO is not positive, treatment for subclinical hypothyroidism is not currently recommended.
Worldwide about one billion people are estimated to be iodine deficient; however, it is unknown how often this results in hypothyroidism. In large population-based studies in Western countries with sufficient dietary iodine, 0.3–0.4% of the population have overt hypothyroidism. A larger proportion, 4.3–8.5%, have subclinical hypothyroidism. Of people with subclinical hypothyroidism, 80% have a TSH level below the 10 mIU/l mark regarded as the threshold for treatment. Children with subclinical hypothyroidism often return to normal thyroid function, and a small proportion develops overt hypothyroidism (as predicted by evolving antibody and TSH levels, the presence of celiac disease, and the presence of a goiter).
Women are more likely to develop hypothyroidism than men. In population-based studies, women were seven times more likely than men to have TSH levels above 10 mU/l. 2–4% of people with subclinical hypothyroidism will progress to overt hypothyroidism each year. The risk is higher in those with antibodies against thyroid peroxidase. Subclinical hypothyroidism is estimated to affect approximately 2% of children; in the adults subclinical hypothyroidism is more common in the elderly, and in Caucasians. There is a much higher rate of thyroid disorders, the most common of which is hypothyroidism, in individuals with Down syndrome and Turner syndrome.
Very severe hypothyroidism and myxedema coma is rare, with it estimated to occur in 0.22 per million people a year. The majority of cases occur in women over 60 years of age, although it may happen in all age groups.
Most hypothyroidism is primary in nature. Central/secondary hypothyroidism affects 1:20,000 to 1:80,000 of the population, or about one out of every thousand people with hypothyroidism.
The link between the thyroid gland and myxedema was established in the late 19th century when people and animals who had had their thyroid removed showed improvement in symptoms with transplantation of animal thyroid tissue. Iodine had been discovered in seaweed in 1811 by Bernard Courtois, and iodine intake was linked with goiter size in 1820 by Jean-Francois Coindet. Gaspard Adolphe Chatin proposed in 1852 that endemic goiter was the result of not enough iodine intake, and Eugen Baumann demonstrated iodine in thyroid tissue in 1896.
In 1891, the English physician George Redmayne Murray introduced subcutaneously injected sheep thyroid extract, followed shortly after by an oral formulation. Purified thyroxine was introduced in 1914 and in the 1930s synthetic thyroxine became available, although desiccated animal thyroid extract remained widely used. Liothyronine was identified in 1952.
In veterinary practice, dogs are the species most commonly affected by hypothyroidism. The majority of cases occur as a result of primary hypothyroidism, of which two types are recognized: lymphocytic thyroiditis, which is probably immune-driven and leads to destruction and fibrosis of the thyroid gland, and idiopathic atrophy, which leads to the gradual replacement of the gland by fatty tissue. There is often lethargy, cold intolerance, exercise intolerance, and weight gain. Furthermore, skin changes and fertility problems are seen in dogs with hypothyroidism, as well as a number of other symptoms. The signs of myxedema can be seen in dogs, with prominence of skin folds on the forehead, and cases of myxedema coma are encountered. The diagnosis can be confirmed by blood test, as the clinical impression alone may lead to overdiagnosis. Lymphocytic thyroiditis is associated with detectable antibodies against thyroglobulin, although they typically become undetectable in advanced disease. Treatment is with thyroid hormone replacement.
Other species that are less commonly affected include cats and horses, as well as other large domestic animals. In cats, hypothyroidism is usually the result of other medical treatment such as surgery or radiation. In young horses, congenital hypothyroidism has been reported predominantly in Western Canada and has been linked with the mother's diet.
- Longo, DL; Fauci, AS; Kasper, DL; Hauser, SL; Jameson, JL; Loscalzo, J (2011). "341: disorders of the thyroid gland". Harrison's principles of internal medicine. (18th ed.). New York: McGraw-Hill. ISBN 007174889X.
- Khandelwal D, Tandon N; Tandon (January 2012). "Overt and subclinical hypothyroidism: who to treat and how". Drugs (Review) 72 (1): 17–33. doi:10.2165/11598070-000000000-00000. PMID 22191793.
- Ebert, E. C. (July 2010). "The thyroid and the gut". Journal of Clinical Gastroenterology 44 (6): 402–6. doi:10.1097/MCG.0b013e3181d6bc3e. PMID 20351569.
- Garber, JR; Cobin, RH; Gharib, H; Hennessey, JV; Klein, I; Mechanick, JI; Pessah-Pollack, R; Singer, PA et al. (December 2012). "Clinical Practice Guidelines for Hypothyroidism in Adults". Thyroid 22 (12): 1200–1235. doi:10.1089/thy.2012.0205. PMID 22954017.
- Klubo-Gwiezdzinska, J; Wartofsky, L (March 2012). "Thyroid emergencies". Medical Clinics of North America 96 (2): 385–403. doi:10.1016/j.mcna.2012.01.015. PMID 22443982.
- van den Boogaard, E; Vissenberg, R; Land, JA et al. (2011). "Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review". Human Reproduction Update (Review) 17 (5): 605–19. doi:10.1093/humupd/dmr024. PMID 21622978.
- Vissenberg, R; van den Boogaard, E; van Wely, M et al. (July 2012). "Treatment of thyroid disorders before conception and in early pregnancy: a systematic review". Human Reproduction Update (Review) 18 (4): 360–73. doi:10.1093/humupd/dms007. PMID 22431565.
- Negro R, Stagnaro-Green A; Stagnaro-Green (October 2014). "Diagnosis and management of subclinical hypothyroidism in pregnancy". BMJ 349 (10): g4929. doi:10.1136/bmj.g4929. PMID 25288580.
- Counts, D; Varma, SK (Jul 2009). "Hypothyroidism in children". Pediatrics in Review 30 (7): 251–8. doi:10.1542/pir.30-7-251. PMID 19570923.
- Pearce, EN (Feb 2012). "Update in lipid alterations in subclinical hypothyroidism". The Journal of Clinical endocrinology and Metabolism 97 (2): 326–33. doi:10.1210/jc.2011-2532. PMID 22205712.
- Chandna, Shalu; Bathla, Manish (July 2011). "Oral manifestations of thyroid disorders and its management". Indian J Endocrinol Metab 15 (Suppl2): S113–6. doi:10.4103/2230-8210.83343. PMC 3169868. PMID 21966646.
- Brown, RS (2013). "Autoimmune thyroiditis in childhood". Journal of Clinical Research in Pediatric Endocrinology (Review). 5 Suppl 1 (4): 45–9. doi:10.4274/jcrpe.855. PMC 3608006. PMID 23154164.
- Gaitonde, DY; Rowley, KD; Sweeney, LB (August 2012). "Hypothyroidism: an update". American Family Physician (Review) 86 (3): 244–51. PMID 22962987.
- Persani, L (September 2012). "Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges". The Journal of Clinical endocrinology and Metabolism (Review) 97 (9): 3068–78. doi:10.1210/jc.2012-1616. PMID 22851492.
- Chakera, AJ; Pearce, SH; Vaidya, B (2012). "Treatment for primary hypothyroidism: current approaches and future possibilities". Drug Design, Development and Therapy (Review) 6: 1–11. doi:10.2147/DDDT.S12894. PMC 3267517. PMID 22291465.
- Stagnaro-Green, A (February 2012). "Approach to the patient with postpartum thyroiditis". The Journal of Clinical endocrinology and Metabolism (Review) 97 (2): 334–42. doi:10.1210/jc.2011-2576. PMID 22312089.
- Donaldson, M; Jones, J (2013). "Optimising outcome in congenital hypothyroidism; current opinions on best practice in initial assessment and subsequent management". Journal of Clinical Research in Pediatric Endocrinology (Review). 5 Suppl 1 (4): 13–22. doi:10.4274/jcrpe.849. PMC 3608009. PMID 23154163.
- Maia, AL; Goemann, IM; Meyer, EL; Wajner, SM (17 March 2011). "Type 1 iodothyronine deiodinase in human physiology and disease: Deiodinases: the balance of thyroid hormone". Journal of Endocrinology 209 (3): 283–297. doi:10.1530/JOE-10-0481. PMID 21415143.
- Cheng, SY; Leonard, JL; Davis, PJ (Apr 2010). "Molecular aspects of thyroid hormone actions". Endocrine Reviews 31 (2): 139–70. doi:10.1210/er.2009-0007. PMC 2852208. PMID 20051527.
- Stagnaro-Green, A; Abalovich, M; Alexander, E; Azizi, F; Mestman, J; Negro, R; Nixon, A; Pearce, EN; Soldin, OP; Sullivan, S; Wiersinga, W; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum (Oct 2011). "Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum". Thyroid 21 (10): 1081–125. doi:10.1089/thy.2011.0087. PMC 3472679. PMID 21787128.
- So, M; MacIsaac, RJ; Grossmann M (August 2012). "Hypothyroidism". Australian Family Physician 41 (8): 556–62. PMID 23145394.
- Dons, Robert F.; Jr, Frank H. Wians (2009). Endocrine and metabolic disorders clinical lab testing manual (4th ed.). Boca Raton: CRC Press. p. 10. ISBN 9781420079364.
- Bona, G; Prodam, F; Monzani, A (2013). "Subclinical hypothyroidism in children: natural history and when to treat". Journal of Clinical Research in Pediatric Endocrinology (Review). 5 Suppl 1 (4): 23–8. doi:10.4274/jcrpe.851. PMC 3608012. PMID 23154159.
- Fatourechi, V. (2009). "Subclinical Hypothyroidism: An Update for Primary Care Physicians". Mayo Clinic Proceedings (Review) 84 (1): 65–71. doi:10.4065/84.1.65. PMC 2664572. PMID 19121255.
- The Practice Committee of the American Society for Reproductive Medicine (November 2012). "Evaluation and treatment of recurrent pregnancy loss: a committee opinion". Fertility and Sterility 98 (5): 1103–1111. doi:10.1016/j.fertnstert.2012.06.048. PMID 22835448.
- Regan, L; Backos M; Rai, R (2011-05-19). "The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage". Green-top Guideline No. 17. London: Royal College of Obstetricians and Gynaecologists. Retrieved 26 December 2013.
- Charlton, K; Skeaff, S (November 2011). "Iodine fortification". Current Opinion in Clinical Nutrition and Metabolic Care 14 (6): 618–624. doi:10.1097/MCO.0b013e32834b2b30. PMID 21892078.
- World Health Organization, UNICEF, ICCIDD (2008). Assessment of iodine deficiency disorders and monitoring their elimination (3rd ed.). Geneva: World Health Organization. ISBN 9789241595827.
- e-Library of Evidence for Nutrition Actions (eLENA) (2014). "Iodine supplementation during pregnancy". World Health Organization. Retrieved 5 March 2014.
- "Reaching Optimal Iodine Nutrition in Pregnant and Lactating Women and Young Children". Joint Statement by the World Health Organization and United Nations Children's Fund. World Health Organization. 2007. Retrieved 5 March 2014.
- Public Health Committee of the American Thyroid Association; Becker, DV; Braverman, LE; Delange, F; Dunn, JT; Franklyn, JA; Hollowell, JG; Lamm, SH; Mitchell, ML; Pearce, E; Robbins, J; Rovet, JF (Oct 2006). "Iodine supplementation for pregnancy and lactation-United States and Canada: recommendations of the American Thyroid Association". Thyroid 16 (10): 949–51. doi:10.1089/thy.2006.16.949. PMID 17042677.
- American Academy of Pediatrics; Rose, SR; Section on Endocrinology and Committee on Genetics, American Thyroid Association; Brown, RS; Public Health Committee, Lawson Wilkins Pediatric Endocrine Society; Foley, T; Kaplowitz, PB; Kaye, CI; Sundararajan, S; Varma, SK (Jun 2006). "Update of newborn screening and therapy for congenital hypothyroidism". Pediatrics 117 (6): 2290–303. doi:10.1542/peds.2006-0915. PMID 16740880.
- Pollitt, RJ (Jun 2009). "Newborn blood spot screening: new opportunities, old problems". Journal of Inherited Metabolic Disease 32 (3): 395–9. doi:10.1007/s10545-009-9962-0. PMID 19412659.
- LeFevre, ML (24 March 2015). "Screening for Thyroid Dysfunction: U.S. Preventive Services Task Force Recommendation Statement.". Annals of internal medicine. PMID 25798805.
- Malt, EA; Dahl, RC; Haugsand, TM; (February 2013). "Health and disease in adults with Down syndrome". Tidsskrift for Den Norske Legeforening (Review) 133 (3): 290–4. doi:10.4045/tidsskr.12.0390. PMID 23381164.
- Cascorbi, I (August 2012). "Drug interactions--principles, examples and clinical consequences". Deutsches Ärzteblatt International (Review) 109 (33–34): 546–55. doi:10.3238/arztebl.2012.0546. PMC 3444856. PMID 23152742.
- Escobar-Morreale, HF; Botella-Carretero, JI; Escobar del Rey, F; Morreale de Escobar, G (August 2005). "Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine". The Journal for Clinical Endocrinology and Metabolism (Review) 90 (8): 4946–54. doi:10.1210/jc.2005-0184. PMID 15928247.
- British Thyroid Association Executive Committee (November 2007). "Armour Thyroid(USP) and combinedthyroxine/tri-iodothyronine as thyroid hormone replacement" (PDF). British Thyroid Association. Retrieved 25 December 2013.
- Wiersinga, Wilmar M.; Duntas, Leonidas; Fadeyev, Valentin; Nygaard, Birte; Vanderpump, Mark P.J. (2012). "2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism". European Thyroid Journal 1 (2): 55–71. doi:10.1159/000339444. PMID 24782999.
- Ebling PR (2011). "ESA Position Statement on Desiccated Thyroid or Thyroid Extract". Endocrine Society of Australia. Retrieved 13 December 2013.
- Ochs, N; Auer, R; Bauer, DC (June 2008). "Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality". Annals of Internal Medicine (Meta-analysis) 148 (11): 832–45. doi:10.7326/0003-4819-148-11-200806030-00225. PMID 18490668.
- Villar HC, Saconato H, Valente O, Atallah AN; Saconato; Valente; Atallah (2007). Villar, Heloisa Cerqueira Cesar Esteves, ed. "Thyroid hormone replacement for subclinical hypothyroidism". Cochrane Database of Systematic Reviews (Review, meta-analysis) (3): CD003419. doi:10.1002/14651858.CD003419.pub2. PMID 17636722.
- The Royal College of Physicians, The Association for Clinical Biochemistry The Society for Endocrinology, The British Thyroid Association et al. (19 November 2008). "The Diagnosis and Management of Primary Hypothyroidism" (pdf). Retrieved 2013-06-16.
- Reid, SM; Middleton, P; Cossich, MC; Crowther, CA; Bain, E (2013). Reid, Sally M, ed. "Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy". Cochrane Database of Systematic Reviews 5 (5): CD007752. doi:10.1002/14651858.CD007752.pub3. PMID 23728666.
- Cooper, DS; Braverman LE, ed. (2012-07-12). Werner & Ingbar's the thyroid : a fundamental and clinical text (10th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health. p. 552. ISBN 145112063X.
- Monzani, A; Prodam, F; Rapa, A; Moia, S; Agarla, V; Bellone, S; Bona, G (Jan 2013). "Endocrine disorders in childhood and adolescence. Natural history of subclinical hypothyroidism in children and adolescents and potential effects of replacement therapy: a review". European Journal of Endocrinology 168 (1): R1–R11. doi:10.1530/EJE-12-0656. PMID 22989466.
- Leung, AM; Braverman, LE; Pearce, EN (Nov 13, 2012). "History of U.S. iodine fortification and supplementation". Nutrients 4 (11): 1740–6. doi:10.3390/nu4111740. PMC 3509517. PMID 23201844.
- Murray, GR (Oct 10, 1891). "Note on the Treatment of Myxoedema by Hypodermic Injections of an Extract of the Thyroid Gland of a Sheep". British Medical Journal 2 (1606): 796–7. doi:10.1136/bmj.2.1606.796. PMC 2273741. PMID 20753415.
- Fox, EL (Oct 29, 1892). "A Case of Myxoedema Treated by Taking Extract of Thyroid by the Mouth". British Medical Journal 2 (1661): 941. doi:10.1136/bmj.2.1661.941. PMC 2421284. PMID 20753901.
- "Hypothyroidism". Merck Veterinary Manual, 10th edition (online version). 2012. Retrieved 2013-12-25.
- Mooney, CT (May 2011). "Canine hypothyroidism: A review of aetiology and diagnosis". New Zealand Veterinary Journal 59 (3): 105–114. doi:10.1080/00480169.2011.563729. PMID 21541883.
- "Hypothyroidism; a booklet for patients and their families" (PDF). American Thyroid Association. 2013. Retrieved 2013-12-25.
- "UK Guidelines for the use of thyroid function tests". The Association for Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation. 2006. Retrieved 2013-12-25.